These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37140357)

  • 21. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is riluzole a new drug for Alzheimer's disease?
    Whitcomb DJ; Molnár E
    J Neurochem; 2015 Oct; 135(2):207-9. PubMed ID: 26451974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice.
    Lesuis SL; Kaplick PM; Lucassen PJ; Krugers HJ
    Neuropharmacology; 2019 May; 150():175-183. PubMed ID: 30794835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotective effects of riluzole in Huntington's disease.
    Squitieri F; Ciammola A; Colonnese C; Ciarmiello A
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):221-2. PubMed ID: 17987289
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Riluzole: a glimmer of hope in the treatment of motor neurone disease.
    Kiernan MC
    Med J Aust; 2005 Apr; 182(7):319-20. PubMed ID: 15804220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
    Silk AW; Saraiya B; Groisberg R; Chan N; Spencer K; Girda E; Shih W; Palmeri M; Saunders T; Berman RM; Coric V; Chen S; Zloza A; Vieth J; Mehnert JM; Malhotra J
    Eur J Med Res; 2022 Jul; 27(1):107. PubMed ID: 35780243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyotrophic lateral sclerosis, excitotoxicity and riluzole.
    Obrenovitch TP
    Trends Pharmacol Sci; 1998 Jan; 19(1):9-11. PubMed ID: 9509893
    [No Abstract]   [Full Text] [Related]  

  • 30. Riluzole promotes motor and respiratory recovery associated with enhanced neuronal survival and function following high cervical spinal hemisection.
    Satkunendrarajah K; Nassiri F; Karadimas SK; Lip A; Yao G; Fehlings MG
    Exp Neurol; 2016 Feb; 276():59-71. PubMed ID: 26394202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of amyotrophic lateral sclerosis with riluzole.
    Neatherlin JS
    J Neurosci Nurs; 1998 Aug; 30(4):257-60. PubMed ID: 9791781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.
    Saavedra JM
    Cell Mol Neurobiol; 2016 Mar; 36(2):259-79. PubMed ID: 26993513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease.
    Elkahloun AG; Hafko R; Saavedra JM
    Alzheimers Res Ther; 2016 Jan; 8():5. PubMed ID: 26822027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications.
    Pinky PD; Pfitzer JC; Senfeld J; Hong H; Bhattacharya S; Suppiramaniam V; Qureshi I; Reed MN
    Neuroscientist; 2023 Aug; 29(4):461-471. PubMed ID: 35073787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Chintha N; Jupudi S; Palathoti N; Bharathi J J; Justin A
    J Biomol Struct Dyn; 2023; 41(22):12620-12631. PubMed ID: 36644856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
    Doraiswamy PM
    CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.